Generic Seysara Availability
Last updated on Apr 10, 2025.
Seysara is a brand name of sarecycline, approved by the FDA in the following formulation(s):
SEYSARA (sarecycline hydrochloride - tablet;oral)
-
Manufacturer: ALMIRALL
Approval date: October 1, 2018
Strength(s): EQ 60MG BASE [RLD], EQ 100MG BASE [RLD], EQ 150MG BASE [RLD]
Is there a generic version of Seysara available?
No. There is currently no therapeutically equivalent version of Seysara available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Seysara. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Substituted tetracycline compounds
Patent 8,318,706
Issued: November 27, 2012
Inventor(s): Kim Oak & Assefa Haregewein & Honeyman Laura
Assignee(s): Paratek Pharmaceuticals, Inc.The present invention pertains, at least in part, to novel substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms.
Patent expiration dates:
- May 1, 2031✓✓✓
- May 1, 2031
-
Substituted tetracycline compounds for treatment of inflammatory skin disorders
Patent 8,513,223
Issued: August 20, 2013
Inventor(s): Assefa Haregewein & Bhatia Beena & Draper Michael P. & Honeyman Laura & Kim Oak & Molnar Dennis P.
Assignee(s): Paratek Pharmaceuticals, Inc.Methods and compositions for the treatment of skin disorders (e.g., acne, rosacea) are described.
Patent expiration dates:
- December 7, 2029✓
- December 7, 2029
-
Crystalline salts of (4S,4AS,5AR,12AS)-4-dimethylamino-3,10,12,12A-tetrahydroxy-7-[methoxy(methyl)amino)-methyl] acid amide and methods of using the same
Patent 9,255,068
Issued: February 9, 2016
Inventor(s): Coulter; Catherine et al.
Assignee(s): Warner Chilcott Company, LLC (Fajardo, PR); Paratek Pharmaceuticals, Inc. (Boston, MA)A crystalline mono hydrochloride salt of (4S,4aS,5aR,12aS)-4-dimethylamino-3,10,12,12a-tetrahydroxy-7-[(methoxy(methyl)amino)-methyl]-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacene-2-carboxylic acid amide is disclosed having improved stability. In addition, a crystalline mono mesylate salt and crystalline mono sulfate salt of (4S,4aS,5aR,12aS)-4-dimethylamino-3,10,12,12a-tetrahydroxy-7-[(methoxy(methyl)amino)-methyl]-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacene-2-carboxylic acid amide are also disclosed having improved stability. A pharmaceutical composition containing the crystalline salts and methods of treating inflammatory skin disorders and bacterial infections comprising administering the crystalline salts are also disclosed.
Patent expiration dates:
- February 9, 2033✓✓✓
- February 9, 2033✓✓✓
- February 9, 2033
-
Substituted tetracycline compounds for treatment of inflammatory skin disorders
Patent 9,481,639
Issued: November 1, 2016
Inventor(s): Assefa Haregewein & Bhatia Beena & Draper Michael P. & Honeyman Laura & Kim Oak K. & Molnar Dennis P.
Assignee(s): Paratek Pharmaceuticals, Inc.Methods and compositions for the treatment of skin disorders (e.g., acne, rosacea) are described.
Patent expiration dates:
- August 10, 2028✓
- August 10, 2028
More about Seysara (sarecycline)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (11)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: tetracyclines
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
